Literature DB >> 18362222

Higher detection rate of JAK2 mutation using plasma.

Wanlong Ma, Hagop Kantarjian, Xi Zhang, Weimin Sun, Arlene M Buller, Iman Jilani, Joyce G Schwartz, Francis Giles, Maher Albitar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18362222     DOI： 10.1182/blood-2008-02-139188

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.

Authors:  Mohamed E Salama; Sabina I Swierczek; Kimberly Hickman; Andrew Wilson; Josef T Prchal
Journal:  Blood       Date:  2009-07-02       Impact factor: 22.113

2.  Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.

Authors:  Todd S Laughlin; Alison R Moliterno; Brady L Stein; Paul G Rothberg
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

Review 3.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

4.  Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Xiuiang Wang; Zeev Estrov; Susan O'Brien; Maher Albitar
Journal:  Leuk Res       Date:  2010-10-15       Impact factor: 3.156

Review 5.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors:  B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

6.  Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Chen-Hsiung Yeh; Zhong J Zhang; Srdan Verstovsek; Maher Albitar
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

7.  Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.

Authors:  Wanlong Ma; Hagop Kantarjian; Benjamin Bekele; Amber C Donahue; Xi Zhang; Zhong J Zhang; Susan O'Brien; Elihu Estey; Zeev Estrov; Jorge Cortes; Michael Keating; Francis Giles; Maher Albitar
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

8.  Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.

Authors:  Dino Veneri; Enrico Capuzzo; Giovanna de Matteis; Massimo Franchini; Elisabetta Baritono; Marco Benati; G Pietro Solero; Achille Ambrosetti; Giulia Quaresmini; Giovanni Pizzolo
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

9.  Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.

Authors:  Adam Albitar; Wanlong Ma; Ivan DeDios; Jeffrey Estella; Inhye Ahn; Mohammed Farooqui; Adrian Wiestner; Maher Albitar
Journal:  Oncotarget       Date:  2017-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.